In #JPM2023 news, $QSI Quantum-SI also presented on January 12, 2023. The company launched their Platinum protein sequencer a few weeks ago.
The technology is not too dissimilar from the DNA sequencing Ion Torrent technology: a dense array of wells capture the proteins, then single molecule sequencing takes place independently in each well, and the different reactions for the different aminoacids are captured.
These different amino acids can include post-translational modifications (PTMs) which are common in most mammals and it's fair to say that they are little understood compared to fields such as genomics or transcriptomics.
Compared to the traditional Mass Spectrometry approach, where signals from small peptides, constituents of the sample proteins, are matched against a large database of peptides that have been seen before, the $QSI Quantum-SI approach is truly "de novo".
Quantum-SI are not alone in this cohort of new companies encompassing different methods in what we can call #NextGenerationProteomicsSequencing (NGPS), and others like Encodia and Erisyon are putting together de novo protein sequencers with alternative tech.
The rest of the companies in the list, such as $SLGC Somalogic, $OLK Olink, $NAUT Nautilus or $QTRX Quanterix are working on high-throughput identification methods, sometimes limited to small panels.
Quantum-SI is partnering with Aviva Systems Biology and Vizit to further delve into the full spectrum of analyzable proteins, and have the tools to understand these in the context of diseases or drug mechanisms-of-action.
Since the instrument is not expensive, there will be labs that may want to try it out. One example user case the company put in a slide deck is the following: you are producing some protein, purify it, run a gel, and there are several bands in the gel. Which one is your
purified protein, and what's in the other bands?
It sounds like a simple question, and there may be very simple legitimate ways to get to the answer with Mass Spec approaches, but undoubtedly, many will want to give Quantum-SI Platinum instrument and methods a try now.
More on NGPS at

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Albert Vilella

Albert Vilella Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @AlbertVilella

Jan 13
In #JPM2023, $NAUT Nautilus Bio didn't make their slides available, but they have a slide deck from an investor meeting in December 2022. They intend to launch their Proteome Analysis Platform in Mid-2024. Image
They see a market opportunity of $25B, where 50% would be BioPharma customers, and 20% Academic and Research. Image
One of the biggest piece of news is that $NAUT Nautilus Bio recently partnered with Abcam to enhance their affinity reagent development program. Image
Read 7 tweets
Jan 13
In #JPM2023 news, $SEER also presented. They are another of the Next Generation Proteomics Sequencing players. One of their USPs is that they have an approach capable of finding different protein variants that would be undistinguishable with affinity-based approaches. Image
This includes slice variants, where the "Peptide Level" identification allows them to detect meaningful differences where other approaches are not able to. ImageImage
Since their method is based on peptides, they can go into the 1M+ elements per run, where panel-based affinity methods are limited to the thousands or maybe tens of thousands. Image
Read 4 tweets
Jan 13
In #JPM2023 news, $OLK Olink presented and showed good numbers, especially for their high-plex segment. Image
Olink believes they have <5% penetration on the mid-plex TAM Image
A growing portfolio of products, the Explore 3072 panel queries ~3,000 proteins with minimal biological sample requirements. ImageImage
Read 4 tweets
Jan 13
Their estimated TAM is $85B, which is short of the other estimate touted at JPM for Proteomics as a whole, of $130B.
Quanterix does Single Molecule Array Technology (SIMOA), a Digital version of the equivalent ELISA Analog assay. Being able to go as low as femtograms per millilitre is a discovery tool for Early Disease Detection.
Read 6 tweets
Jan 13
The SomaLogic technology binds SOMAmer reagents to thousands of individual proteins. The unbound proteins are washed away, and the SOMAmers are flown into an array that measures the relative concentration of the bound proteins with a colorimetric array.
It can detect up to 10 logs of dynamic range and started at 55 microliters of volume sample per assay.
Read 8 tweets
Jan 13
They recently acquired $ISO Isoplexius, "the only single-cell platform enabling functional proteomics" (although people doing CITE-seq and co. on other single-cell technologies may differ).
Isoplexis recently announced their Duomic Multiomics technology, with combined ELISA Protein assyas with Multi-Omics of the kind people do with single-cells. It's available for human and mouse panels of cell types.
Read 7 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!